Ob/Gyn Medical News about Breast Cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
New England Journal of Medicine, 12/27/07

Miller K et al. - In a trial to compare the efficacy and safety of paclitaxel with paclitaxel plus bevacizumab as initial treatment for metastatic breast cancer, it was found that paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone

Methods

Patients were assigned to receive 90 mg of paclitaxel per square meter of body-surface area on days 1, 8, and 15 every 4 weeks, either alone or with 10 mg of bevacizumab per kilogram of body weight on days 1 and 15
The primary end point was progression-free survival; overall survival was a secondary end point

Results

722 patients were enrolled
Paclitaxel plus bevacizumab significantly prolonged progression-free survival and increased the objective response rate
Overall survival rate, however, was similar in the two groups
Grade 3 or 4 hypertension, proteinuria, headache, and cerebrovascular ischemia were more frequent in patients receiving paclitaxel plus bevacizumab
Infection was more common in patients receiving paclitaxel plus bevacizumab, but febrile neutropenia was uncommon

<< Previous
Medicaid Preferred Drug Lists' Costs to Physicians

Next >>
Risk of preterm delivery in relation to vaginal bleeding in early...